Document Detail

Infliximab use in Crohn's disease: impact on health care resources in the UK.
MedLine Citation:
PMID:  16148549     Owner:  NLM     Status:  MEDLINE    
OBJECTIVE: To quantify the impact of infliximab therapy on health care resource utilization in the UK. METHODS: A retrospective audit was undertaken at seven centres in the UK, which reviewed patient notes for a period of 6 months before and 6 months after an initial infliximab infusion. Details of hospital admissions, outpatient visits, operations, diagnostic procedures, drug usage, and overall efficacy were collected. Results were compared for the two 6 month study periods. RESULTS: A total of 205 patients (62% female, median age 33 years) with moderate/severe Crohn's disease were audited. The majority of patients had chronic active disease (62%) and most received one infusion initially (72%). Clinicians rated 74% of responses as good to excellent and patients 72%. Most patients had concomitant immunosuppression (pre: 75%, post: 75%). Approximately half of the patients (45%) stopped taking steroids, with a further 34% having a dosage reduction. A fall of 1093 inpatient days was seen (1435 vs. 342) in the 6 months following infliximab administration. There were seven fewer operations, 33 fewer examinations under anaesthetic, and 99 fewer diagnostic procedures. Outpatient visits were similar pre- versus post- (555 vs. 534). The total reduction in direct costs amounted to an estimated pounds 591,006. Three hundred and fifty-three infliximab infusions were administered at an estimated cost of pounds 562,719. Thus, there was a net reduction of pounds 28,287 or pounds 137.98 per patient. CONCLUSIONS: Infliximab appears to be a potentially cost effective treatment for selected patients based on the reduced number of inpatient stays, examinations under anaesthetic, and diagnostic procedures over a 6 month period.
Derek P Jewell; Jack Satsangi; Alan Lobo; Christopher Probert; Alastair Forbes; Subrata Ghosh; Jon Shaffer; Markus Frenz; Hazel Drummond; Gill Troy; Sue Turner; Lisa Younge; Lyn Evans; Mark Moosa; Barry Rodgers-Gray; Scot Buchan
Related Documents :
19267159 - Intraoperative ultrasound versus mammographic needle localization for ductal carcinoma ...
21838909 - Repeated treatment of recurrent uncomplicated plasmodium falciparum malaria in senegal ...
8595649 - Cost-effectiveness analyses of the conversion of patients with non-insulin-dependent di...
15921059 - Cost-effectiveness of nutritional counseling for obese patients and patients at risk of...
17186199 - Long-term cost-effectiveness of clopidogrel in patients with acute coronary syndrome wi...
19736179 - (cost)-effectiveness of self-treatment of exacerbations on the severity of exacerbation...
21794179 - Effects of different initial bundle tensioning strategies on the outcome of double-bund...
25352659 - An aggregate score to predict the risk of large pleural effusion after pulmonary lobect...
23918219 - Outcome of a multimodality approach to the management of idiopathic subglottic stenosis.
Publication Detail:
Type:  Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  European journal of gastroenterology & hepatology     Volume:  17     ISSN:  0954-691X     ISO Abbreviation:  Eur J Gastroenterol Hepatol     Publication Date:  2005 Oct 
Date Detail:
Created Date:  2005-09-08     Completed Date:  2006-03-28     Revised Date:  2009-10-16    
Medline Journal Info:
Nlm Unique ID:  9000874     Medline TA:  Eur J Gastroenterol Hepatol     Country:  England    
Other Details:
Languages:  eng     Pagination:  1047-52     Citation Subset:  IM    
Gastroenterology Unit, University of Oxford, Sheffield, UK.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Aged, 80 and over
Antibodies, Monoclonal / economics,  therapeutic use*
Antirheumatic Agents / economics,  therapeutic use*
Cost-Benefit Analysis
Crohn Disease / drug therapy*,  economics,  surgery
Drug Costs / statistics & numerical data
Epidemiologic Methods
Great Britain
Health Care Costs / statistics & numerical data
Health Resources / utilization*
Health Services Research
Hospitalization / statistics & numerical data
Middle Aged
Treatment Outcome
Tumor Necrosis Factor-alpha / antagonists & inhibitors
Reg. No./Substance:
0/Antibodies, Monoclonal; 0/Antirheumatic Agents; 0/Tumor Necrosis Factor-alpha; 0/infliximab

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Course of disease, drug treatment and health-related quality of life in patients with inflammatory b...
Next Document:  Report of a collaborative trial to investigate the performance of the R5 enzyme linked immunoassay t...